Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
  • LinkedIn
  • Instagram
Research ArticleOncology Briefs

Chemotherapy basics for family physicians

Anna N. Wilkinson and Nureen Sumar
Canadian Family Physician January 2022; 68 (1) 30-34; DOI: https://doi.org/10.46747/cfp.680130
Anna N. Wilkinson
Assistant Professor in the Department of Family Medicine at the University of Ottawa in Ontario, a family physician with the Ottawa Academic Family Health Team, a general practitioner oncologist at The Ottawa Hospital Cancer Centre, Program Director of PGY-3 FP-Oncology, Chair of the Cancer Care Member Interest Group at the College of Family Physicians of Canada, and Regional Cancer Primary Care Lead for Champlain Region.
MSc MD CCFP FCFP
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nureen Sumar
Clinical Assistant Professor in the Department of Family Medicine at the University of Calgary in Alberta, a faculty member in the Department of Haematology-Oncology at Aga Khan University in Nairobi, Kenya, and Clinical Associate at Alberta Health Services in Edmonton.
MSc MD CCFP
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF
Loading

Despite the explosion of novel cancer therapies, chemotherapy remains the backbone of cancer treatment. Family physicians learn little about chemotherapy during their training, but are often required to manage toxicities of these treatments for their patients.1 This brief will summarize chemotherapy essentials for family physicians.

Overview

All chemotherapy drugs work by decreasing cellular growth and proliferation. The mechanisms of these drugs vary from competitively inhibiting cross-linking DNA, to blocking enzymes involved in DNA replication (eg, topoisomerases) and impairing spindle microtubule formation (Figure 1).2,3 BC Cancer’s drug manual is an excellent resource for more information about chemotherapy drugs (http://www.bccancer.bc.ca/health-professionals/clinical-resources/cancer-drug-manual).

Figure 1.
  • Download figure
  • Open in new tab
Figure 1.

Mechanisms of action of various chemotherapy drugs

Chemotherapy intent

The term adjuvant is commonly used in oncology and means in addition to definitive treatment (ie, surgery, radiation). In the curative setting, neoadjuvant treatment is used to downstage (ie, reduce cancers to an earlier and more treatable stage) or improve operability of cancers before definitive therapy. Concurrent treatment is given as a radiosensitizer during radiation therapy. Adjuvant therapy is employed to eradicate microscopic disease after definitive treatment.2

Palliative chemotherapy is a noncurative treatment, aiming to decrease tumour burden and improve quantity and quality of life. Palliative chemotherapy differs from curative chemotherapy in that the number of cycles is not fixed.4 Efficacy of palliative chemotherapy is assessed using computed tomography scans to periodically restage the cancer, in concert with monitoring clinical status and biochemical markers when applicable. An unexplained decline in clinical status should prompt restaging investigations to assess for progression. Patients may remain on therapy for months or years, changing regimens when there is disease progression and stopping when they are too unwell or have decided not to pursue further treatment, or when there are no further treatment options. The toxicity of treatment must reflect the goals of therapy: for example, a higher toxicity with increased efficacy may be acceptable in a curative setting, but unacceptable in the palliative setting where quality of life is paramount.

Practical considerations

Chemotherapy efficacy is increased at higher doses; however, because these drugs affect all rapidly dividing cells, doses are limited by the amount of damage to normal tissues, especially to hematologic cells. By delivering chemotherapy in cycles, dose intensity can be maintained, allowing bone marrow time to recover between treatments. Cycle lengths generally range from 14 to 28 days, with the expected nadir in neutrophil counts occurring at 7 to 14 days posttreatment.5 The combination of chemotherapy drugs with differing mechanisms of action is synergistic and can allow lower doses of drugs to be given, with decreased development of resistance by cancer cells (Table 1).6,7

View this table:
  • View inline
  • View popup
Table 1.

Chemotherapy regimens used for common malignancies

Although many chemotherapies are delivered via bolus intravenous infusion, 5-fluorouracil (5-FU) can also be administered via continuous infusion over 48 hours. Several chemotherapy agents, such as capecitabine (which is metabolized to 5-FU) and etoposide, are given orally.7 Consideration must be given to use of central venous access devices such as a port or a peripherally inserted central catheter if the chemotherapy is a vesicant (eg, doxorubicin, epirubicin, vinorelbine, and vincristine).8

Bloodwork is monitored before each cycle of chemotherapy, and treatment proceeds if blood counts are appropriate. If patients tolerate treatment poorly, or if their blood counts do not recover before the next cycle of treatment, dose reductions or cycle delays can be considered, depending on the urgency of treating at optimal dose. In the curative setting, where it is critical to maintain dose intensity and remain on schedule, granulocyte colony-stimulating factor can be administered after each cycle to stimulate the bone marrow to increase neutrophil production and prevent febrile neutropenia.9 Patients must have a reasonable performance status to tolerate chemotherapy, which in practical terms equates with being well enough to be out of bed at least 50% of the time, or Eastern Cooperative Oncology Group grade 2 (Table 2).10

View this table:
  • View inline
  • View popup
Table 2.

ECOG scale of performance status

Caregivers and patients should treat bodily fluids as cytotoxic and wear gloves if handling emesis, stool, or urine for the first 48 hours after treatment. During this time period, patients should sit down to urinate and close the toilet lid before flushing to avoid splashing bodily fluids.11 Contraception should always be employed. As it is unclear whether chemotherapy drugs can be passed through semen, oral, or vaginal secretions during sexual activity, barrier methods are advised until 7 days after the last chemotherapy treatment.12

Management of acute toxicities

Myelosuppression occurs with most chemotherapy drugs and manifests clinically as fatigue, dyspnea, bleeding, and infections. Other acute toxicities are drug specific (Table 3, Figure 2).2,13 Chemotherapy toxicities are graded from 1 (mild) to 5 (related to death).14 Patients who require admission to hospital generally have grade 3 or 4 reactions.

View this table:
  • View inline
  • View popup
Table 3.

Common acute chemotherapy toxicities by drug

Figure 2.
  • Download figure
  • Open in new tab
Figure 2.

Schematic of the most common locations of toxicities of selected chemotherapy drugs

Chemotherapy agents are classified as having high to low emetogenic potential, and are known to cause anticipatory, acute, and delayed (day 2 to 5 posttreatment) nausea.15 Antiemetics target neurotransmitter receptors that are involved in provoking emesis. An effective 4-drug prophylactic antiemetic regimen is recommended for patients who receive highly emetogenic drugs: a neurokinin-1 receptor antagonist (eg, aprepitant), a 5-HT3 receptor antagonist (eg, ondansetron), a dopamine antagonist (eg, olanzapine), and dexamethasone.16,17 Intravenous hydration is a helpful adjunct for patients with breakthrough nausea. Delayed nausea may be improved by lengthening the course of dexamethasone, and anxiolytics are effective for anticipatory nausea. Practitioners should be aware that 5-HT3 receptor antagonists will cause substantial constipation.

Chemotherapy-induced peripheral neuropathy (CIPN) occurs with oxaliplatin, docetaxel, and paclitaxel, which are common treatments for colon and breast cancer.18 Chemotherapy-induced peripheral neuropathy manifests in a stocking and glove distribution with sensory symptoms, causing impairment of fine motor tasks and gait stability. Early recognition of CIPN and dose adjustment of chemotherapy are key, as once present, neuropathy is only partially reversible. The only treatment with any evidence of benefit for CIPN is duloxetine, although gabapentinoids and tricyclic antidepressants may be trialed.19,20

Capecitabine or 5-FU can cause inflammation and ulceration throughout the gastrointestinal system. In the mouth, this presents as mucositis, causing pain and decreased oral intake with potential for dehydration and increased risk of bacteremia.21 Enteritis, or inflammation of the small bowel, results in watery diarrhea, depleting fluids and electrolytes. Irinotecan also causes diarrhea because of direct mucosal damage. Once alternate causes such as infection, laxatives, and partial bowel obstruction have been ruled out, symptomatic therapies can be employed. Management of mucositis and diarrhea based on cancer agency guidelines is presented in Table 4.21-25

View this table:
  • View inline
  • View popup
Table 4.

Management of chemotherapy-related mucositis and diarrhea

Conclusion

This brief overview of chemotherapy provides family physicians with the tools to understand and participate in their patients’ cancer treatments. Understanding the practical considerations of chemotherapy administration and how to manage common chemotherapy toxicities will permit primary care physicians to better support their patients and effectively treat potential cancer therapy side effects.

Footnotes

  • Competing interests

    None declared

  • This article is eligible for Mainpro+ certified Self-Learning credits. To earn credits, go to www.cfp.ca and click on the Mainpro+ link.

  • La traduction en français de cet article se trouve à www.cfp.ca dans la table des matières du numéro de janvier 2022 à la page e5.

  • Copyright © 2022 the College of Family Physicians of Canada

References

  1. 1.↵
    1. Yip SM,
    2. Meyers DE,
    3. Sisler J,
    4. Wycliffe-Jones K,
    5. Kucharski E,
    6. Elser C, et al.
    Oncology education for family medicine residents: a national needs assessment survey. BMC Med Educ 2020;20(1):283.
    OpenUrl
  2. 2.↵
    1. Chang AE,
    2. Ganz PA,
    3. Hayes DF,
    4. Kinsella T,
    5. Pass HI,
    6. Schiller JH, et al.
    editors. Oncology: an evidence-based approach. New York, NY: Springer; 2006.
  3. 3.↵
    1. Hasudungan A.
    Oncology. Sydney, Aust: Armando Hasudungan Biology and Medicine Videos; 2021. Available from: https://armandoh.org/subjects/oncology/. Accessed 2021 Nov 24.
  4. 4.↵
    1. Roeland EJ,
    2. LeBlanc TW.
    Palliative chemotherapy: oxymoron or misunderstanding? BMC Palliat Care 2016;15:33.
    OpenUrl
  5. 5.↵
    Hematology and associated laboratory tests. In: Clinical pharmacy guide: cancer drug treatment assessment and review 5th edition. Vancouver, BC: BC Cancer; 2020. Available from: http://www.bccancer.bc.ca/pharmacy-site/Documents/Clinical%20Pharmacy%20Guide/cpg3b-hematology-lab-tests.pdf. Accessed 2021 Nov 24.
  6. 6.↵
    1. Kerr DJ,
    2. Haller DG,
    3. van de Velde CJ,
    4. Baumann M
    , editors. Oxford textbook of oncology. 3rd ed. Oxford, UK: Oxford University Press; 2016.
  7. 7.↵
    1. Eguzo K,
    2. Jacobs C,
    3. Umezurike C,
    4. Eseigbe E,
    5. Ginsburg O,
    6. Hawley P.
    Where there is no oncologist: manual of practical oncology in resource-limited settings. 2nd ed. Nlagu, Nigeria: Marjorie Bash Foundation; 2017. Available from: https://www.researchgate.net/publication/318885762_Where_There_is_no_Oncologist_Manual_of_Practical_Oncology_in_Resource-Limited_Settings. Accessed 2021 Nov 24.
  8. 8.↵
    BC Cancer extravasation hazard table. Vancouver, BC: BC Cancer; 2021. Available from: http://www.bccancer.bc.ca/drug-database-site/Documents/Extravasation%20Hazard%20Table.pdf. Accessed 2021 Nov 24.
  9. 9.↵
    1. Aapro M,
    2. Boccia R,
    3. Leonard R,
    4. Camps C,
    5. Campone M,
    6. Choquet S, et al.
    Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations. Support Care Cancer 2017;25(11):3295-304. Epub 2017 Aug 25.
    OpenUrl
  10. 10.↵
    1. Oken MM,
    2. Creech RH,
    3. Tormey DC,
    4. Horton J,
    5. Davis TE,
    6. McFadden ET, et al.
    Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5(6):649-55.
    OpenUrlCrossRefPubMed
  11. 11.↵
    How to safely handle cancer medications and body fluids at home. Toronto, ON: Cancer Care Ontario. Available from: https://www.cancercareontario.ca/sites/ccocancercare/files/assets/HomeSafety.pdf. Accessed 2021 Nov 24.
  12. 12.↵
    Intimacy and sex: for people with cancer and their partners. Toronto, ON: Cancer Care Ontario. Available from: https://www.cancercareontario.ca/sites/ccocancercare/files/IntimacyandSex.pdf. Accessed 2021 Nov 24.
  13. 13.↵
    1. Baquiran DC,
    2. Gallagher J.
    Lippincott’s cancer chemotherapy handbook. 2nd ed. Alphen aan den Rijn, The Netherlands: Wolters Kluwer; 2001.
  14. 14.↵
    Common terminology criteria for adverse events (CTCAE). Bethesda, MD: National Institutes of Health; 2020. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm. Accessed 2021 Nov 24.
  15. 15.↵
    1. Navari RM,
    2. Aapro M.
    Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med 2016;374(14):1356-67.
    OpenUrlCrossRefPubMed
  16. 16.↵
    2019 antiemetic recommendations for chemotherapy-induced nausea and vomiting: a clinical practice guideline. Toronto, ON: Cancer Care Ontario; 2019. Available from: https://www.cancercareontario.ca/sites/ccocancercare/files/guidelines/full/2019AntiemeticRecommendationsChemotherapyInducedNauseaVomiting.pdf. Accessed 2021 Nov 24.
  17. 17.↵
    Antiemetic guidelines. Vancouver, BC: BC Cancer; 2017. Available from: http://www.bccancer.bc.ca/chemotherapy-protocols-site/Documents/Supportive%20Care/SCNAUSEA%20Appendix%20-%20Antiemetic%20Guidelines.pdf. Accessed 2021 Nov 24.
  18. 18.↵
    1. Tofthagen C,
    2. McAllister RD,
    3. Visovsky C.
    Peripheral neuropathy caused by paclitaxel and docetaxel: an evaluation and comparison of symptoms. J Adv Pract Oncol 2013;4(4):204-15.
    OpenUrlPubMed
  19. 19.↵
    Chemotherapy induced peripheral neuropathy. Clinical practice guideline SUPP-010—version 1. Edmonton, AB: Alberta Health Services; 2019. Available from: https://www.albertahealthservices.ca/assets/info/hp/cancer/if-hp-cancer-guide-supp010-peripheral-neuropathy.pdf. Accessed 2021 Nov 24.
  20. 20.↵
    1. Hershman DL,
    2. Lacchetti C,
    3. Dworkin RH,
    4. Lavoie Smith EM,
    5. Bleeker J,
    6. Cavaletti G, et al.
    Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2014;32(18):1941-67. Epub 2014 Apr 14.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Elad S,
    2. Cheng KKF,
    3. Lalla RV,
    4. Yarom N,
    5. Hong C,
    6. Logan RM, et al.
    MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 2020;126(19):4423-31. Epub 2020 Jul 28. Erratum in: Cancer 2021;127(19):3700.
    OpenUrlPubMed
  22. 22.
    Oral care management tips for healthcare professionals: mucositis, candidiasis, xerostomia. Edmonton, AB: Alberta Health Services; 2019. Available from: https://www.albertahealthservices.ca/assets/info/hp/cancer/if-hp-cancer-guide-symptom-summary-oral-care.pdf. Accessed 2021 Nov 24.
  23. 23.
    Oral care (mouth care). Toronto, ON: Cancer Care Ontario. Available from: https://www.cancercareontario.ca/en/symptom-management/3156. Accessed 2021 Nov 24.
  24. 24.
    Diarrhea. Toronto, ON: Cancer Care Ontario. Available from: https://www.cancercareontario.ca/en/symptom-management/3151. Accessed 2021 Nov 24.
  25. 25.↵
    Symptom management guidelines: diarrhea. Vancouver, BC: BC Cancer; 2018. Available from: http://www.bccancer.bc.ca/nursing-site/Documents/4.%20Diarrhea.pdf. Accessed 2021 Nov 24.
PreviousNext
Back to top

In this issue

Canadian Family Physician: 68 (1)
Canadian Family Physician
Vol. 68, Issue 1
1 Jan 2022
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Chemotherapy basics for family physicians
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Chemotherapy basics for family physicians
Anna N. Wilkinson, Nureen Sumar
Canadian Family Physician Jan 2022, 68 (1) 30-34; DOI: 10.46747/cfp.680130

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Chemotherapy basics for family physicians
Anna N. Wilkinson, Nureen Sumar
Canadian Family Physician Jan 2022, 68 (1) 30-34; DOI: 10.46747/cfp.680130
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Overview
    • Chemotherapy intent
    • Practical considerations
    • Management of acute toxicities
    • Conclusion
    • Footnotes
    • References
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF

Related Articles

  • Principes de base de la chimiothérapie à l’intention des médecins de famille
  • PubMed
  • Google Scholar

Cited By...

  • Feuilles de route de la survivance au cancer
  • Cancer survivorship road map
  • Colon cancer in primary care
  • Le cancer du colon en soins primaires
  • Google Scholar

More in this TOC Section

  • Having hard conversations
  • Cardiotoxicity of cancer treatment
  • Cancer survivorship road map
Show more Oncology Briefs

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • LinkedIn
  • Instagram
  • RSS Feeds

Copyright © 2025 by The College of Family Physicians of Canada

Powered by HighWire